We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+16.12%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.01B
AUM Growth
-$101M
(-4.8%)
Cap. Flow
-$306M
Cap. Flow
% of AUM
-15.22%
Top 10 Holdings %
Top 10 Hldgs %
62.57%
Holding
41
New
5
Increased
9
Reduced
5
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DaVita
DVA
|
+$73.7M |
| 2 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$61.7M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$54.8M |
| 4 |
Biogen
BIIB
|
+$47.2M |
| 5 |
AGN
Allergan plc
AGN
|
+$43.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSRO
TESARO, Inc.
TSRO
|
+$208M |
| 2 |
McKesson
MCK
|
+$96.7M |
| 3 |
CELG
Celgene Corp
CELG
|
+$96.1M |
| 4 |
GSK
GSK
|
+$76.4M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
+$43.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.93% |
| 2 | Miscellaneous | 14.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Sutro Biopharma
STRO
$275M
| $6.83M | 0.34% |
60,000
| – | – |
|
|
ELGX
27
DELISTED
Endologix Inc
ELGX
| $6.15M | 0.31% |
930,001
+1
| +0% | +$7 |
|
28
Surgery Partners
SGRY
$1.79B
| $1.81M | 0.09% |
160,084
| – | – |
|
|
29
Alnylam Pharmaceuticals
ALNY
$31.9B
| – | – |
-600,000
| Closed | -$43.7M |
|
30
Bausch Health
BHC
$2.12B
| – | – |
-1,000,000
| Closed | -$18.5M |
|
|
31
CALL
Bristol-Myers Squibb
BMY
$130B
| – | – |
-1,000,000
| Closed | -$52M |
|
32
CALL
Cardinal Health
CAH
$54.1B
| – | – |
-1,000,000
| Closed | -$44.6M |
|
|
33
GSK
GSK
$100B
| – | – |
-1,600,000
| Closed | -$76.4M |
|
34
HCA Healthcare
HCA
$91.8B
| – | – |
-250,000
| Closed | -$31.1M |
|
|
35
McKesson
MCK
$105B
| – | – |
-875,000
| Closed | -$96.7M |
|
36
Puma Biotechnology
PBYI
$477M
| – | – |
-1,300,000
| Closed | -$26.5M |
|
37
CALL
Viatris
VTRS
$19.1B
| – | – |
-1,000,000
| Closed | -$27.4M |
|
|
ARNA
38
DELISTED
Arena Pharmaceuticals Inc
ARNA
| – | – |
-500,000
| Closed | -$19.5M |
|
|
AGN
39
CALL
DELISTED
Allergan plc
AGN
| – | – |
-1,000,000
| Closed | -$134M |
|
|
TSRO
40
DELISTED
TESARO, Inc.
TSRO
| – | – |
-2,800,000
| Closed | -$208M |
|
|
CELG
41
DELISTED
Celgene Corp
CELG
| – | – |
-1,500,000
| Closed | -$96.1M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Camber Capital Management held 41 positions worth $2.01B, down 4.8% from $2.11B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Camber Capital Management withdrew a net $306M in Q1 2019, closing 13 positions and reducing 5 holdings. Its most notable exit was TESARO, Inc., an estimated $208M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 88% a quarter earlier, followed by Miscellaneous.
Against the trend, Camber Capital Management opened a new position in Teva Pharmaceutical Industries Limited worth $54.9M.
- Camber Capital Management's largest Q1 2019 buy was Teva Pharmaceutical Industries Limited: 3,500,000 shares worth $54.9M.
- Camber Capital Management added most to DaVita in Q1 2019, an estimated $73.7M increase.
- Camber Capital Management's biggest Q1 2019 reduction was Tenet Healthcare, cutting an estimated $37M.
- Camber Capital Management fully exited TESARO, Inc. in Q1 2019, selling an estimated $208M.
- Camber Capital Management's ten largest holdings make up 63% of its $2.01B portfolio in Q1 2019.
- Camber Capital Management opened 5 new positions and closed 13 in Q1 2019.
- Camber Capital Management's portfolio value fell 4.8% quarter-over-quarter to $2.01B.
Based on Camber Capital Management's 13F filing for Q1 2019, filed 15 May 2019.